| Literature DB >> 21723724 |
Stephen Connolly1, Lilian Alcaraz, Andrew Bailey, Elaine Cadogan, Jadeen Christie, Anthony R Cook, Adrian J Fisher, Stephen Hill, Alexander Humphries, Anthony H Ingall, Zoe Kane, Stuart Paine, Garry Pairaudeau, Michael J Stocks, Alan Young.
Abstract
Starting with the molecular scaffold of the DA(2)/β(2) dual agonist sibenadet (Viozan™), a number of molecular changes were incorporated, which were designed to increase the potency and selectivity of the target molecule, and improve its pharmacokinetics. Through this process a novel, high potency, full β(2)-agonist with high selectivity and long duration capable of being dosed once daily has been discovered.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21723724 DOI： 10.1016/j.bmcl.2011.05.097
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823